|
|
Article: New Data Show Early Use Of Anti-Platelet Therapy Reduced Combined Death Or Subsequent Heart Attacks In High-Risk Heart Attack Patients; -- Results From Crusade Support Treatment Guidelines --.
- Article from:
- PR Newswire
- Article date:
- September 17, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Treating high-risk acute coronary syndrome (ACS) patients with an anti-platelet medicine, known as a glycoprotein (GP) IIb-IIIa inhibitor, before interventional procedures such as angioplasty significantly reduced the in-hospital incidence of combined death or subsequent heart attacks, according to research presented today at the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C. The data were collected from CRUSADE, a national quality improvement initiative that retrospectively examines the treatment of high-risk chest pain disorder patients at hospitals in the United States. CRUSADE is led by the Duke Clinical Research Institute (DCRI) ...